Genmab is seeking to out-license zalutumumab, a fully human antibody targeting EGFr, following results of our phase III study in head and neck cancer announced March 2010. 

Please see the following announcements regarding Zalutumumab Phase III clinical results:
Headline Results announcement
June 2010 ASCO presentation

A confidential data package is available after execution of a suitable non-disclosure agreement (CDA). For further information please contact our Business Development department at licensing@genmab.com.